Dr. Kiran Gupta holds a PhD in Molecular Biology and serves as a technical due diligence advisor for venture capital firms. With 12 years in R&D and investment, she bridges the gap between the lab bench and the boardroom. She evaluates innovations in healthcare and energy sectors.
Dr. Kiran Gupta earned her PhD in Molecular Biology from Imperial College London, where her research focused on gene-editing mechanisms. She transitioned from academic research to the commercial sector, working as a Senior Analyst for a London-based deep tech venture fund. Her expertise lies in evaluating the scientific viability and market potential of frontier technologies, including CRISPR-Cas9 therapeutics, phage therapy, and the emerging field of quantum sensing. Kiran is adept at explaining complex innovations like AlphaFold's impact on drug discovery or the engineering challenges of nuclear fusion's STEP programme. She writes to help investors and business leaders understand the regulatory hurdles within the NHS and the practical timelines for scaling technologies like solid-state batteries and lab-grown meat. Her analysis is grounded in rigorous scientific method, cutting through hype to reveal genuine commercial opportunities in the UK's scientific landscape.